Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
Read more
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Read more
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Click Here
Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
Read more
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Read more
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Click Here
Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
Read more
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Read more
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Click Here

Heterogeneous and curated biobank of live-cell tumor samples retains highly reproducible drug response data for drug and biomarker discovery

White paper validates highly reproducible drug response data.
Results enable AI platform to model and predict patient outcomes on historical samples

Leveraging more than 20 years of longitudinal patient and drug response data, Predictive
Oncology verified and validated that the cryopreserved tumor samples preserved in the
company’s live-cell biobank continue to produce accurate drug response data that is consistent
with their initial clinical testing results with 100% concordance.

These findings clearly demonstrate the fidelity of the specimens in Predictive Oncology’s
biobank and the ability to connect and subsequently analyze these historical samples relative to
patient outcomes. The ability to introduce patient heterogeneity in the discovery and
development stages increases the Probability of Technical Success (PTS) and reduces the risk
inherent in all aspects of the drug development pipeline.

Complete the form below to download the white paper.

Related Content: